Work

Reply to Verweij et al

Year: 2007

Type: letter

Source: Clinical Infectious Diseases

DOI: 10.1086/518388

Authors: R. E. Greene, H. T. Schlamm, J.-W. Oestmann, P. Stark, C. Durand, O. Lortholary, J. R. Wingard, R. Herbrecht, P. Ribaud, T. F. Patterson, P. F. Troke, D. W. Denning, J. E. Bennett, B. E. d. Pauw, R. H. Rubin

Institutions: Brigham and Women's Hospital, Massachusetts General Hospital, Pfizer (United States), Stiftung Charité, Charité – Universitätsmedizin Berlin, University of California San Diego, Institut Pasteur, Hôpital Saint-Louis, University of Florida, Hôpital d'Hautepierre, The University of Texas at San Antonio Health Science Center, University of Manchester, National Institute of Allergy and Infectious Diseases

Language: French

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Pfizer Pharmaceuticals, Janssen Pharmaceuticals

OpenAlex ID: W2161183340

Cites: 6

Cited by: 3

Related to: 10